Professor Babatunde Salako
The Director General, Nigerian Institute of Medical Research (NIMR), Professor Babatunde Salako has called for the implementation of the study of antiretroviral therapy in Nigeria for the betterment of HIV/AIDS patients.
The DG NIMR made this call during the presentation of a report conducted between September 2013 and September 2016 with theme, HIV drug resistance: Implication for optimizing Antiretroviral Therapy in Abuja.
Prof. Salako noted that the NIMR has the responsibility to conduct research on diseases of public health concern.
He said that the institute would ensure that the results of such research are properly disseminated to the relevant stakeholders in the health sector and Nigerians in general.
He informed that there was a new method of treating HIV and AIDS patients in Nigeria. He added that the method was achieved as a result of collaboration between the University of Jos, University College Ibadan, Harvard T. H Chan School of public health, Boston –USA, APIN Public Health Initiative and GLOBOMICS LLC, Atlanta – USA as Consulting partner.
Earlier in his remark, the Director General of National Agency for the Control of AIDS (NACA), Dr Sanni Aliyu, said that the finding of the study was very important in improving the treatment of HIV patients in the country. He assured that the report would be disseminated to the relevant stakeholders in the country
The Osun State House of Assembly has resolved to impose a six-month prison term or…
Governor Abdullahi Sule of Nasarawa State has dismissed growing concerns that Nigeria may be drifting…
A human rights lawyer and activist, Barrister Christopher Chidera, has called for sanctions against Appeal…
Speaker of the Edo State House of Assembly (EDHA), Hon. Blessing Agbebaku, on Tuesday, led…
He further describes the situation as unacceptable and calls for urgent intervention to protect road…
Cheaper petrol means lower operational costs in businesses like shipping, manufacturing, and agriculture, which boosts…
This website uses cookies.